| Literature DB >> 34422220 |
Dionysia Theofylaktou1, Işıl Takan2,3, Gökhan Karakülah2,3, Gökay Mehmet Biz4, Vaso Zanni1, Athanasia Pavlopoulou2,3, Alexandros G Georgakilas1.
Abstract
Natural products, like turmeric, are considered powerful antioxidants which exhibit tumor-inhibiting activity and chemoradioprotective properties. Nowadays, there is a great demand for developing novel, affordable, efficacious, and effective anticancer drugs from natural resources. In the present study, we have employed a stringent in silico methodology to mine and finally propose a number of natural products, retrieved from the biomedical literature. Our main target was the systematic search of anticancer products as anticancer agents compatible to the human organism for future use. In this case and due to the great plethora of such products, we have followed stringent bioinformatics methodologies. Our results taken together suggest that natural products of a great diverse may exert cytotoxic effects in a maximum of the studied cancer cell lines. These natural compounds and active ingredients could possibly be combined to exert potential chemopreventive effects. Furthermore, in order to substantiate our findings and their application potency at a systems biology level, we have developed a representative, user-friendly, publicly accessible biodatabase, NaturaProDB, containing the retrieved natural resources, their active ingredients/fractional mixtures, the types of cancers that they affect, and the corresponding experimentally verified target genes.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34422220 PMCID: PMC8376429 DOI: 10.1155/2021/9993518
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Bar graph depicting the distribution of natural products (orange) and genes (blue) with respect to cancer types.
Figure 2STRING output functional network of the 81 genes/gene products. The nodes represent molecules and the connecting lines (edges) indicate an interaction confidence score above 0.9.
Figure 3Bar plot depicting the overrepresented cancer-related pathways across target genes.
List of the selected organisms/foods, active compounds/extracts, effective inhibitory concentration, affected cancer type, and target genes.
| Source | Active substance/extract | Effective concentration | Cancer type | Target gene |
|---|---|---|---|---|
| Ethyl acetate fraction of | IC50: 73.3 and 92.7 | Hepatoma | AKT1, MAPK1, MMP2, MMP9, PIK3CD, TIMP2 | |
|
| Beta-caryophyllene and caryophyllene oxide fractions of | Maximum inhibition: 50 | Lymphoma; neuroblastoma | ATM, BAK1, BAX, BCL2, CASP8, CASP9, MDM2, PTGS2 |
| Allicin | Maximum inhibition: 90 | Glioblastoma | BAX, BCL2 | |
| N-Benzyl-N-methyldecan-1-amine (NBNMA) | Maximum inhibition: 50 | Leukemia | BAD, BAX, BCL2, BCL2L1, BIRC2, CASP3, CASP8, CASP9, CDK2, CDKN1A, XIAP | |
| Aloin (AL) | IC50: 10 | Colorectal cancer | BCL2L1, MYC, STAT3 | |
| Cardanol monoene (CM) extracted from cashew nut shell liquid (CNSL) | IC50: 23.15 ± 2.42 | Melanoma | BAX, BCL2, TP53, CASP3, PARP1 | |
|
| Ethyl acetate extract of | IC50: 11.43 ± 1.87 | Colon cancer | CASP3, CASP7, CASP8, CASP9, BAX, BCL2 |
| Resveratrol | IC50: 46.81 ± 1.26 | Breast cancer; cervical cancer | CDK4, CDKN1A, MAPK3, TP53 | |
| Peanut skin procyanidins (PSP) | IC50: 48.57 | Prostate cancer | BAX, BCL2, CASP3, TP53 | |
| Natural antioxidants (NAOs) from spinach extract | MIC: 3.2 mg/ml for 24 h treatment | Prostate cancer | CDK2, CDKN1A, E2F1, RB1, RBL1 | |
| Black pepper | Piperine | IC50: 54 ± 5 | Colon cancer | AKT1, BIRC5, CCND1, CCND3, CDKN1A, CDKN1B, MAPK8 |
| Black soybean | Black soybean extract | IC50: 3.69 mg/ml for 72 h treatment | Gastric cancer | BAX, BCL2, CASP3 |
| Indole-3-carbinol (I3C) | Maximum inhibition: 50 | Acute myeloid leukemia (AML); leukemia | AKT1, BCL2, BIRC2, BIRC5, CCND1, MMP9, NFKB1, NOS2, PTGS2, TNF, TRAF1, XIAP | |
| Ethanol extracts of raw chestnut (RCE) | Maximum inhibition: 200 | Gastric cancer | ASP3, CASP7, CASP8, FASLG, HLA-DRB1,PARP1, TNFSF10, XIAP | |
|
| Flavonoids | IC50: 99 | Gastric cancer | CASP3, CCNB1, CDK1, PARP1 |
| Curcumin | Maximum inhibition: 25 | Bladder cancer | NFKB1, PTGS2 | |
| Curcumin | IC50: 11 to 46 | Pancreatic cancer | CXCL8, NFKB1, PTGS2 | |
| Curcumin | Maximum inhibition: 50 | Thyroid cancer | SMAD2, SMAD3, TGFB1 | |
|
| Yuanhuadine | Maximum inhibition: 32 nM for 72 h treatment | Lung cancer | AKT1, CDK2, CDK4, CDKN1A, MYC |
| Sporamin | Maximum inhibition: 100 | Pancreatic cancer | BAX, BCL2, BCL2L1, NFKB1 | |
| Juglanin | IC50: 20.07 to 29.13 | Breast cancer | BAD, BAX, BCL2, CASP3, CASP8, CASP9, CDC25C, CDK1, CDKN1B, CHEK2 | |
| Juglone | IC50: 8 | Leukemia | AKT1, CASP3, MTOR, PIK3CD | |
| Lebanese | Daucus carota oil extract (DCOE) | IC50: 10.2 ± 0.90 to 19.1 ± 0.98 | Skin Cancer | AKT1, BCl2, BAX |
| Hexane fraction of N. sublateritium extract (HFNS) | IC50: 200 | Breast Cancer | JUN, MAPK14, MAPK8, MAPK9, MMP9, NFKB1, SERPINE1, TIMP2 | |
|
| IC50: 120 to 140 | Thyroid cancer | BAX, BCL2, CASP3, PARP1 | |
| Red sorghum bran | 3-Deoxyanthocyanidins | IC50: 300 | Breast Cancer | BCL2, TP53 |
| Sanguinarine | IC50: 1 | Oral cancer | AKT1, CASP3, CASP9, PIK3CD |
MIC: minimum inhibitory concentration. IC50: half-maximal effective inhibitory concentration.
Figure 4Bipartite network displaying TCGA-derived cancer-gene associations. The interactions are presented in a circular mode; the cancer types are shown at the center and the genes at the periphery. The size of the nodes is proportional to their connectivity degree.
Differentially expressed genes in diverse TCGA-derived cancers.
| Gene | TCGA cancer type | Status |
|---|---|---|
| ATM | OV | Down |
| BAD | DLBC,THYM | Up |
| BAK1 | PAAD | Up |
| BAX | DLBC,GBM,PAAD,TGCT,THYM | Up |
| BCL2 | CESC,OV,UCS | Down |
| BCL2 | DLBC,LAML,THYM | Up |
| BCL2L1 | PAAD | Up |
| BIRC5 | LAML | Down |
| BIRC5 | BLCA,BRCA,CESC,COAD,DLBC,GBM,LIHC,LUAD,LUSC,OV,PAAD,READ,SKCM,STAD,THYM,UCEC,UCS | Up |
| CASP3 | DLBC,GBM,PAAD,THYM | Up |
| CASP7 | DLBC,THYM | Up |
| CASP9 | OV | Down |
| CCNB1 | LAML | Down |
| CCNB1 | ACC,BLCA,BRCA,CESC,COAD,DLBC,GBM,LIHC,LUAD,LUSC,OV,PAAD,READ,SKCM,STAD,THYM,UCEC,UCS | Up |
| CCND1 | LAML | Down |
| CCND1 | COAD,DLBC,KIRC,LGG,OV,PAAD,READ,STAD,THCA,THYM | Up |
| CCND3 | PAAD | Up |
| CDC25C | LAML | Down |
| CDC25C | CESC,COAD,DLBC,GBM,OV,READ,STAD,THYM,UCEC,UCS | Up |
| CDK1 | LAML | Down |
| CDK1 | ACC,BLCA,BRCA,CESC,COAD,DLBC,GBM,LIHC,LUAD,LUSC,OV,PAAD,READ,STAD,THYM,UCEC,UCS | Up |
| CDK2 | DLBC,GBM,SKCM,THYM | Up |
| CDK4 | DLBC,GBM,LGG,SARC,TGCT,THYM | Up |
| CDKN1A | OV | Down |
| CDKN1A | GBM | Up |
| CHEK2 | DLBC,TGCT,THYM | Up |
| CXCL8 | CESC,COAD,ESCA,GBM,HNSC,PAAD,READ,SKCM,STAD,UCEC | Up |
| E2F1 | BLCA,BRCA,CESC,COAD,DLBC,LIHC,OV,PAAD,READ,THYM,UCEC,UCS | Up |
| HLA-DRB1 | DLBC,GBM,LAML,LGG,OV,PAAD,STAD,TGCT,THYM | Up |
| JUN | SKCM | Down |
| MAPK1 | LAML | Down |
| MAPK3 | PAAD | Up |
| MAPK8 | THYM | Up |
| MDM2 | DLBC,SARC,THYM | Up |
| MMP2 | ACC,CESC,OV,SKCM | Down |
| MMP2 | DLBC,GBM,LAML,LGG,PAAD,THYM | Up |
| MMP9 | THYM | Down |
| MMP9 | BLCA,BRCA,CESC,COAD,ESCA,GBM,HNSC,OV,PAAD,READ,SKCM,STAD,TGCT,THCA,UCEC,UCS | Up |
| MTOR | THYM | Up |
| MYC | COAD,DLBC,GBM,LGG,READ,THYM | Up |
| NFKB1 | THYM | Up |
| NOS2 | COAD,READ | Up |
| PARP1 | DLBC,THYM | Up |
| PIK3CD | SKCM | Up |
| PTGS2 | LAML,PAAD | Up |
| RB1 | GBM,THYM | Up |
| SERPINE1 | KICH,OV | Down |
| SERPINE1 | DLBC,ESCA,GBM,HNSC,PAAD | Up |
| SMAD3 | UCEC | Down |
| SMAD3 | THYM | Up |
| TGFB1 | GBM,LGG,PAAD | Up |
| TIMP2 | BLCA,CESC,OV,UCEC | Down |
| TIMP2 | LAML,PAAD | Up |
| TNFSF10 | KICH | Down |
| TNFSF10 | CESC,LAML,PAAD,TGCT | Up |
| TP53 | DLBC,GBM,LAML,LGG,THYM | Up |
| TRAF1 | OV,UCS | Down |
| TRAF1 | DLBC | Up |
| XIAP | THYM | Up |
Figure 5NaturaProDB workflow showing the (a) example input query, (b) example results page, and (c) “Natural Products Network,” where the node size is proportional to their connectivity degree.